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Etiology of Ulcerative Colitis
The etiology of ulcerative colitis remains unknown, but infective, psychosomatic and immunological theories have been advanced. There is no evidence that it is an infective disorder and systematic studies of the bacterial flora of stools from patients with ulcerative colitis have only shown a quantitative difference compared with controls. No qualitative difference has been found (Cooke 1967 , Gorbach et al. 1968 ). There is also little support for the psychosomatic theory as the most recent studies have failed to show any significant difference between patients and control subjects when a formal psychiatric assessment was made (Feldman et al. 1967) .
Evidence for the role of milk allergy in the etiology of ulcerative colitis has been based on the clinical benefit of a milk-free diet (Wright & Truelove 1965) , and on the finding that patients with this disease frequently have high levels of htmagglutinating antibodies to milk proteins in their serum (Taylor & Truelove 1961) . This latter observation has not always been confirmed, and Jewell & Truelove (1972a) were unable to show any difference in antibody titres to the purified milk proteins between patients and control subjects using the red-cell-linked antigen-antiglobulin reaction. No evidence of reaginic hypersensitivity to the milk proteins has been found (Jewell & Truelove 1972b) . At present, therefore, it would seem that an allergic response to milk proteins is not a factor in the etiology of ulcerative colitis. Present address: Division of Gastroenterology, Stanford University Medical Center, Stanford, California 94305, USA Autoantibodies to colonic epithelial goblet cells have been found in the sera of patients with ulcerative colitis with variable frequency, but the height of the titre does not correlate with the major clinical features (Wright & Truelove 1966) . They cross-react with an antigen in Escherichia coli 014 which suggests that their presence may represent a breakdown of tolerance induced by bacterial antigens (Lagercrantz et al. 1968 ). Various alterations in cellular immune function have been described in ulcerative colitis. These have included the blast transformation oflymphocytes and the inhibition of leukocyte migration in response to a variety of antigens, and the ability of lymphocytes to kill colonic epitheliai cells. This cytotoxic property is lost following colectomy (Shorter et al. 1969 ). However, it remains unknown whether altered cellular immunity has a role in the pathogenesis of the disease or whether it is an epiphenomenon.
Recently it has been shown that antigenantibody complexes are present in the sera of patients with ulcerative colitis (Jewell & Mac-Lennan 1973) . Their molecular weight indicated that they contain less than five molecules of IgG and their presence in serum showed a positive correlation with the severity of the disease as judged clinically and at sigmoidoscopy. It is suggested that immune complexes may be involved in the pathogenesis of ulcerative colitis in at least two ways. First, many of the remote manifestations may be related to the deposition of circulating immune complexes in the tissues. Secondly, it is possible that the formation of immune complexes within the colonic mucosa may perpetuate the inflammatory response and may therefore determine the chronicity of the disease. 
Medical Aspects of Ulcerative Colitis in Childhood
It is generally agreed that ulcerative colitis beginning in childhood frequently runs a severe course. This view is strongly supported by a large-scale study from America of 396 children with ulcerative colitis seen at the Mayo Clinic from 1919 to 1965 (Devroede et al. 1971 ). Follow-up information was complete for 70% and partial for a further 10%. The following conclusions were reached: (1) the death rate was 20% per decade; (2) the risk of carcinoma was 20% per decade after the first decade of the illness;
(3) the risk of death and of carcinoma was particularly high when the entire colon was involved; (4) the prognosis was improved by proctocolectomy.
Devroede et al. found no improvement in the survival of patients seen since 1953, suggesting that corticosteroid therapy has not had much effect on long-term survival. This has not, however, been my own experience; I have found that modem methods of treating ulcerative colitis greatly improve its prognosis, even when it begins in childhood.
Present Methods ofTreatment
Only the main principles of management will be mentioned here. Medical treatment has two objectives: that each attack should be treated promptly, and that every effort should be made to minimize the risk of recurrence. Our own basic regimes are as follows (the doses stated are for an average adult and must be adjusted for children):
(1) For severe attacks: Immediate admission to hospital; nothing but water by mouth; control of water and electrolyte balance by intravenous fluids; blood transfusion and parenteral feeding as required; prednisolone 21-(disodium phosphate) and tetracycline administered by intravenous drip; topical treatment of the distal colon by a rectal drip of hydrocortisone succinate sodium. If the patient responds promptly to this regime he is switched to oral therapy as for a moderate attack. If he does not respond he is treated by urgent radical surgery. The results obtained by this type of regime are given in detail elsewhere (Truelove & Jewell 1973) ; it is equally effective at all ages and about threequarters of patients are in complete remission at the end of a 5-day intravenous course.
(2) For moderate attacks: Admission to hospital; oral regime of prednisolone 10 mg 4 times a day and sulphasalazine (Salazopyrin) 1.0 g 4 times a day; rectal drip of hydrocortisone succinate sodium 100 mg twice a day.
(3) For mild attacks: Outpatient treatment; oral regime of prednisolone 5 mg 4 times a day and Salazopyrin 0.5 g 4 times a day; prednisolone sodium phosphate (Predsol) retention enemata nightly. Hydrocortisone (Cortenema) may be used instead of Predsol.
Prevention ofRelapse
Corticosteroids have been shown to be totally ineffective in preventing recurrence of the disease when used in doses tolerable as maintenance treatment (Truelove & Witts 1959 , Lennard-Jones et al. 1965 . Therefore long-term corticosteroid treatment should not normally be used. When corticosteroids have been successful in checking an attack, they should be continued for about 6 weeks and then tailed off.
In contrast, maintenance treatment with Salazopyrin has been shown to reduce the risk of recurrences (Misiewicz et al. 1965 ) and it has become the mainstay of long-term medical treatment. The question of how long such treatment should be continued is important. Riis et al. (1973) concluded that it is safe to stop treatment after the patient has been symptom-free for a year on Salazopyrin, whereas our own recent results show that Salazopyrin continues to exert a suppressive effect more or less indefinitely (Dissanayake & Truelove 1973). It appears best to continue with Salazopyrin for several years if there are no harmful side-effects.
